haloperidol has been researched along with Acute Brain Injuries in 26 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Haloperidol, which is commonly used to treat agitation in critically ill patients, has been associated with the development of neuroleptic malignant syndrome (NMS)." | 8.85 | Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. ( Bellamy, CJ; Falcione, BA; Kane-Gill, SL; Seybert, AL, 2009) |
| " The following case report describes a patient developing neuroleptic malignant syndrome (NMS) secondary to the use of haloperidol given to control the patient's agitation." | 7.70 | Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. ( Guin-Renfroe, S; Meythaler, JM; Wilkinson, R, 1999) |
| "Haloperidol, which is commonly used to treat agitation in critically ill patients, has been associated with the development of neuroleptic malignant syndrome (NMS)." | 4.85 | Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. ( Bellamy, CJ; Falcione, BA; Kane-Gill, SL; Seybert, AL, 2009) |
| " The following case report describes a patient developing neuroleptic malignant syndrome (NMS) secondary to the use of haloperidol given to control the patient's agitation." | 3.70 | Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. ( Guin-Renfroe, S; Meythaler, JM; Wilkinson, R, 1999) |
| " This constellation of symptoms, known as the neuroleptic malignant syndrome (NMS), partially improved when the neuroleptic medication was stopped, but complete resolution of the syndrome did not occur until the patient was treated with bromocriptine." | 3.67 | Neuroleptic malignant syndrome complicating closed head injury. ( Van Haren, J; Vincent, FM; Zimmerman, JE, 1986) |
| " Case 1 is a description of the subjective experience of a patient with acute orofacial dystonia from promethazine." | 3.66 | Case vignettes of movement disorders. ( Yung, CY, 1983) |
| " These data indicate that chronic administration of RISP and HAL impede behavioral recovery after TBI and impair performance in uninjured controls." | 1.35 | Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury. ( Cheng, JP; Hoffman, AN; Kline, AE; Massucci, JL; Zafonte, RD, 2008) |
| " Carbamazepine at a dosage of 800 mg daily was the most effective medication used." | 1.33 | Auditory hallucinations after right temporal gyri resection. ( Brennan, DM; Stewart, B, 2005) |
| "Neuroleptic malignant syndrome is a rare disorder that manifests with hyperthermia, muscle rigidity and autonomic instability." | 1.32 | Early recognition of neuroleptic malignant syndrome during traumatic brain injury rehabilitation. ( Colachis, SC; Depalma, MJ; Kadyan, V; Mysiw, WJ; Sanderson, JD, 2003) |
| "Variables measured included length of coma, PTA, rehabilitation admission and discharge functional status, and CT scan results." | 1.27 | Agitation in closed head injury: haloperidol effects on rehabilitation outcome. ( Jellinek, HM; Rao, N; Woolston, DC, 1985) |
| "Agitated patients with organic brain disorders represent relatively common diagnostic and management problems." | 1.26 | Treatment of the agitated patient with an organic brain disorder. ( Fauman, MA, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (34.62) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Collison-Ani, E | 1 |
| Faher, A | 1 |
| Au, M | 1 |
| Burrah, G | 1 |
| Wegleiter, K | 1 |
| Hermann, M | 1 |
| Posod, A | 1 |
| Wechselberger, K | 1 |
| Stanika, RI | 1 |
| Obermair, GJ | 1 |
| Kiechl-Kohlendorfer, U | 1 |
| Urbanek, M | 1 |
| Griesmaier, E | 1 |
| Phelps, TI | 1 |
| Bondi, CO | 1 |
| Ahmed, RH | 1 |
| Olugbade, YT | 1 |
| Kline, AE | 3 |
| Hashimoto, K | 1 |
| Hoffman, AN | 2 |
| Cheng, JP | 2 |
| Zafonte, RD | 2 |
| Massucci, JL | 1 |
| Bellamy, CJ | 1 |
| Kane-Gill, SL | 1 |
| Falcione, BA | 1 |
| Seybert, AL | 1 |
| Ma, D | 1 |
| Wilhelm, S | 1 |
| Maze, M | 1 |
| Franks, NP | 1 |
| Kadyan, V | 1 |
| Colachis, SC | 1 |
| Depalma, MJ | 1 |
| Sanderson, JD | 1 |
| Mysiw, WJ | 1 |
| Wilson, MS | 1 |
| Gibson, CJ | 1 |
| Hamm, RJ | 1 |
| Hussain, N | 1 |
| Flumerfelt, BA | 1 |
| Rajakumar, N | 1 |
| Stewart, B | 1 |
| Brennan, DM | 1 |
| Yung, CY | 1 |
| Fowler, SB | 1 |
| Hertzog, J | 1 |
| Wagner, BK | 1 |
| Stanislav, SW | 2 |
| Tang, YP | 1 |
| Noda, Y | 1 |
| Nabeshima, T | 1 |
| Wilkinson, R | 1 |
| Meythaler, JM | 1 |
| Guin-Renfroe, S | 1 |
| Childs, A | 1 |
| Fauman, MA | 1 |
| Pieri, M | 1 |
| Schaffner, R | 1 |
| Pieri, L | 1 |
| Da Prada, M | 1 |
| Haefely, W | 1 |
| Vincent, FM | 1 |
| Zimmerman, JE | 1 |
| Van Haren, J | 1 |
| Rao, N | 1 |
| Jellinek, HM | 1 |
| Woolston, DC | 1 |
| Marsden, CA | 1 |
| Guldberg, HC | 1 |
| Hasselt, PV | 1 |
| Payk, TR | 1 |
| Lapides, MI | 1 |
| Mamtseva, VN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder[NCT03748446] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2019-12-05 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for haloperidol and Acute Brain Injuries
| Article | Year |
|---|---|
Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain Injuries; Cerebral Hemorrhage, Traumatic; Combined Mo | 2009 |
Pharmacological interventions for agitation in head-injured patients in the acute care setting.
Topics: Adult; Brain Injuries; Critical Care; Dose-Response Relationship, Drug; Drug Administration Schedule | 1995 |
24 other studies available for haloperidol and Acute Brain Injuries
| Article | Year |
|---|---|
Cariprazine for treating coprophagia and organic psychosis in a young woman with acquired brain injury.
Topics: Antipsychotic Agents; Brain Injuries; Coprophagia; Female; Haloperidol; Humans; Psychotic Disorders | 2023 |
The sigma-1 receptor agonist 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) protects against newborn excitotoxic brain injury by stabilizing the mitochondrial membrane potential in vitro and inhibiting microglial activation in vivo.
Topics: Animals; Animals, Newborn; Apoptosis; Apoptosis Inducing Factor; Brain Injuries; Caspase 3; Disease | 2014 |
Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Brain Injuries; Bromocriptine; Cognition Disorders; | 2015 |
Targeting the sigma-1 receptor chaperone in the treatment of perinatal brain injury.
Topics: Animals; Brain Injuries; Haloperidol; Membrane Potential, Mitochondrial; Microglia; Receptors, sigma | 2015 |
Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits.
Topics: Animals; Antipsychotic Agents; Brain; Brain Injuries; Cognition; Haloperidol; Male; Motor Activity; | 2008 |
Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury.
Topics: Aggression; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain Injuries; H | 2008 |
Neuroprotective and neurotoxic properties of the 'inert' gas, xenon.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Biomarkers; Brain; Brain Injuries; Dizocilpine Maleate; Fe | 2002 |
Early recognition of neuroleptic malignant syndrome during traumatic brain injury rehabilitation.
Topics: Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Brain Injuries; Haloperidol; Humans; Male; Neur | 2003 |
Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Brain Injuries; Cognition Diso | 2003 |
Glutamatergic regulation of long-term grafts of fetal lateral ganglionic eminence in a rat model of Huntington's disease.
Topics: Animals; Brain Injuries; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dizo | 2004 |
Auditory hallucinations after right temporal gyri resection.
Topics: Adult; Affect; Anticonvulsants; Antipsychotic Agents; Brain Injuries; Carbamazepine; Electroencephal | 2005 |
Case vignettes of movement disorders.
Topics: Adult; Amantadine; Brain Injuries; Clonazepam; Diagnosis, Differential; Dystonia; Female; Haloperido | 1983 |
Cognitive effects of antipsychotic agents in persons with traumatic brain injury.
Topics: Adult; Antipsychotic Agents; Brain Damage, Chronic; Brain Injuries; Cognition Disorders; Haloperidol | 1997 |
Involvement of activation of dopaminergic neuronal system in learning and memory deficits associated with experimental mild traumatic brain injury.
Topics: Animals; Apomorphine; Benzazepines; Brain Injuries; Dopamine; Dopamine Agonists; Dopamine Antagonist | 1997 |
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.
Topics: Adolescent; Amantadine; Brain Injuries; Dopamine Agents; Dopamine Antagonists; Fever; Haloperidol; H | 1999 |
Evaluating the usage of droperidol in acutely agitated persons with brain injury.
Topics: Adult; Antipsychotic Agents; Brain Injuries; Diphenhydramine; Droperidol; Female; Haloperidol; Human | 2000 |
Treatment of the agitated patient with an organic brain disorder.
Topics: Adult; Aged; Antipsychotic Agents; Brain Damage, Chronic; Brain Diseases; Brain Injuries; Haloperido | 1978 |
Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD.
Topics: 5,7-Dihydroxytryptamine; Animals; Apomorphine; Behavior, Animal; Brain Injuries; Catalepsy; Ergoline | 1978 |
Neuroleptic malignant syndrome complicating closed head injury.
Topics: Adult; Brain Injuries; Bromocriptine; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Psy | 1986 |
Agitation in closed head injury: haloperidol effects on rehabilitation outcome.
Topics: Amnesia; Brain; Brain Injuries; Coma; Haloperidol; Humans; Prognosis; Psychomotor Agitation; Retrosp | 1985 |
The role of monoamines in rotation induced or potentiated by amphetamine after nigral, raphe and mesencephalic reticular lesions in the rat brain.
Topics: Amines; Amphetamine; Animals; Behavior, Animal; Brain; Brain Injuries; Catalepsy; Cerebral Cortex; C | 1973 |
Effect of butyrophenones on motor function in rats after recovery from brain damage.
Topics: Animals; Brain Injuries; Butyrophenones; Droperidol; Electromyography; Haloperidol; Motor Activity; | 1973 |
[Course of a schizophrenic process during a traumatic brain injury caused by cerebral fat emboli].
Topics: Adult; Brain Injuries; Embolism, Fat; Female; Haloperidol; Humans; Intracranial Embolism and Thrombo | 1973 |
[On the treatment of psycopath-like states in children with psychotropic drugs after infectious and traumatic disorders of the central nervous system].
Topics: Adolescent; Antidepressive Agents; Antisocial Personality Disorder; Brain Diseases; Brain Injuries; | 1967 |